Cancer Research Technology (CRT), charity Cancer Research UK’s subsidiary to commercialise academic research into oncology treatments, has set up a £50m ($80m) venture fund.

CRT and the European Investment Fund (EIF), a state-backed organisation that is the largest investor – called limited partner – in European venture capital funds, will equally split the commitments for the £50m fund, called CRT Pioneer fund.

The money will be committed in two tranches of £25m – now and in two years’ time…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?